Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M.
Le Tourneau C, et al. Among authors: callens c.
Br J Cancer. 2014 Jul 8;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24.
Br J Cancer. 2014.
PMID: 24762958
Free PMC article.
Clinical Trial.